Allogene Therapeutics Inc - ESG Rating & Company Profile powered by AI
This analysis of Allogene Therapeutics Inc is prepared by All Street Sevva using proprietary machine learning. Complete ESG assessment of Allogene Therapeutics Inc can be accessed by signing up for free. Check the end of the webpage for potential risks for Allogene Therapeutics Inc based on sector, geography and marketcap.
Allogene Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 3.9; made up of an environmental score of 5.3, social score of 2.3 and governance score of 4.0.
3.9
Low ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
1004 | Xeris Pharmaceuticals Inc | 4.0 | High |
1004 | Xenon Pharmaceuticals Inc | 4.0 | High |
... | ... | ... | |
1089 | Allogene Therapeutics Inc | 3.9 | Medium |
1089 | Aclaris Therapeutics Inc | 3.9 | Medium |
1089 | Hua Medicine | 3.9 | Medium |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Allogene Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Does Allogene Therapeutics Inc disclose current and historical energy intensity?
Does Allogene Therapeutics Inc report the average age of the workforce?
Does Allogene Therapeutics Inc reference operational or capital allocation in relation to climate change?
Does Allogene Therapeutics Inc disclose its ethnicity pay gap?
Does Allogene Therapeutics Inc disclose cybersecurity risks?
Does Allogene Therapeutics Inc offer flexible work?
Does Allogene Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Allogene Therapeutics Inc disclose the number of employees in R&D functions?
Does Allogene Therapeutics Inc conduct supply chain audits?
Does Allogene Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Allogene Therapeutics Inc conduct 360 degree staff reviews?
Does Allogene Therapeutics Inc disclose the individual responsible for D&I?
Does Allogene Therapeutics Inc disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Allogene Therapeutics Inc disclose current and / or historical scope 2 emissions?
Does Allogene Therapeutics Inc disclose water use targets?
Does Allogene Therapeutics Inc have careers partnerships with academic institutions?
Did Allogene Therapeutics Inc have a product recall in the last two years?
Does Allogene Therapeutics Inc disclose incidents of discrimination?
Does Allogene Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Has Allogene Therapeutics Inc issued a profit warning in the past 24 months?
Does Allogene Therapeutics Inc disclose parental leave metrics?
Does Allogene Therapeutics Inc disclose climate scenario or pathway analysis?
Does Allogene Therapeutics Inc disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Allogene Therapeutics Inc disclose the pay ratio of women to men?
Does Allogene Therapeutics Inc support suppliers with sustainability related research and development?
Does Allogene Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Allogene Therapeutics Inc reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Allogene Therapeutics Inc involved in embryonic stem cell research?
Does Allogene Therapeutics Inc disclose GHG and Air Emissions intensity?
Does Allogene Therapeutics Inc disclose its waste policy?
Does Allogene Therapeutics Inc report according to TCFD requirements?
Does Allogene Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Allogene Therapeutics Inc disclose energy use targets?
Does Allogene Therapeutics Inc disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Allogene Therapeutics Inc have a policy relating to cyber security?
Have a different question?
Potential Risks for Allogene Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.